Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies

Journal of Pharmaceutical and Biomedical Analysis

Volumn 92, Issue , 2014, Pages 149-159

  Ma, Guo ^a   Lin, Jiayuan ^a   Cai, Weimin ^a   Tan, Bo ^a   Xiang, Xiaoqiang ^a   Zhang, Ying ^a   Zhang, Peng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bilirubin; Glucuronides; HPLC; Liver microsomes; UGT1A1

Indexed keywords

BILIRUBIN; GLUCURONIDES; HPLC; LIVER MICROSOMES; UGT1A1;

ANIMALS; BILIRUBIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 84893875287     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.01.025     Document Type: Article

References (51)

1. Vitek L., Ostrow J.D. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr. Pharm. Des. 2009, 15:2869-2883.
2. Fevery J. Bilirubin in clinical practice: a review. Liver Int. 2008, 28:592-605.
3. Vítek L., Schwertner H.A. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 2007, 43:1-57.
4. Gazzin S., Strazielle N., Tiribelli C., Ghersi-Egea J.F. Transport and metabolism at blood-brain interfaces and in neural cells: relevance to bilirubin-induced encephalopathy. Front. Pharmacol. 2012, 3:89.
5. Ostrow J.D., Pascolo L., Brites D., Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends Mol. Med. 2004, 10:65-70.
6. Shapiro S.M. Bilirubin toxicity in the developing nervous system. Pediatr. Neurol. 2003, 29:410-421.
7. Stevenson D.K., Vreman H.J., Wong R.J. Bilirubin production and the risk of bilirubin neurotoxicity. Semin. Perinatol. 2011, 35:121-126.
8. Crawford J.M., Ransil B.J., Narciso J.P., Gollan J.L. Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis. J. Biol. Chem. 1992, 267:16943-16950.
9. Fevery J., Van D., Michiels R., De Groote J., Heirwegh K.P. Bilirubin conjugates in bile of man and rat in the normal state and in liver disease. J. Clin. Invest. 1972, 51:2482-2492.
10. Muraca M., Rubaltelli F.F., Blanckaert N., Fevery J. Unconjugated and conjugated bilirubin pigments during perinatal development. II. Studies on serum of healthy newborns and of neonates with erythroblastosis fetalis. Biol. Neonate 1990, 57:1-9.
11. Köck K., Brouwer K.L. A perspective on efflux transport proteins in the liver. Clin. Pharmacol. Ther. 2012, 92:599-612.
12. Bosma P.J., Seppen J., Goldhoorn B., Bakker C., Oude Elferink R.P., Chowdhury J.R., Chowdhury N.R., Jansen P.L. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem. 1994, 269:17960-17964.
13. Kadakol A., Ghosh S.S., Sappal B.S., Sharma G., Chowdhury J.R., Chowdhury N.R. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat. 2000, 16:297-306.
14. Gupta B., LeVea C., Litwin A., Fakih M.G. Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clin. Colorectal Cancer 2007, 6:447-449.
15. Rekić D., Clewe O., Röshammar D., Flamholc L., Sönnerborg A., Ormaasen V., Gisslén M., Abelö A., Ashton M. Bilirubin - a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J. 2011, 13:598-605.
16. Rotger M., Taffe P., Bleiber G., Gunthard H.F., Furrer H., Vernazza P., Drechsler H., Bernasconi E., Rickenbach M., Telenti A. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 2005, 192:1381-1386. Swiss HIV Cohort Study.
17. Liu Y., Ramirez J., House L., Ratain M.J. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab. Dispos. 2010, 38:32-39.
18. Peer C.J., Sissung T.M., Kim A., Jain L., Woo S., Gardner E.R., Kirkland C.T., Troutman S.M., English B.C., Richardson E.D., Federspiel J., Venzon D., Dahut W., Kohn E., Kummar S., Yarchoan R., Giaccone G., Widemann B., Figg W.D. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin. Cancer Res. 2012, 18:2099-2107.
19. Zhou J., Tracy T.S., Remmel R.P. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab. Dispos. 2011, 39:322-329.
20. Bartlett M.G., Gourley G.R. Assessment of UGT polymorphisms and neonatal jaundice. Semin. Perinatol. 2011, 35:127-133.
21. Ma G., Wu B., Gao S., Yang Z., Ma Y., Hu M. Mutual regioselective inhibition of human UGT1A1-mediated glucuronidation of four flavonoids. Mol. Pharm. 2013, 10:2891-2903.
22. Sugatani J., Mizushima K., Osabe M., Yamakawa K., Kakizaki S., Takagi H., Mori M., Ikari A., Miwa M. Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 77:597-605.
23. Chawla D., Parmar V. Phenobarbitone for prevention and treatment of unconjugated hyperbilirubinemia in preterm neonates: a systematic review and meta-analysis. Indian Pediatr. 2010, 47:401-407.
24. Ellis E., Wagner M., Lammert F., Nemeth A., Gumhold J., Strassburg C.P., Kylander C., Katsika D., Trauner M., Einarsson C., Marschall H.U. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J. Hepatol. 2006, 44:243-245.
25. Chang T.K. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 2009, 11:590-601.
26. Zhang D.L., Chando T.J., Everett D.W., Patten C.J., Dehal S.S., Humphreys W.G. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 2005, 331:1729-1739.
27. Ostrow J.D., Mukerjee P., Tiribelli C. Structure and binding of unconjugated bilirubin: relevance for physiological and pathophysiological function. J. Lipid Res. 1994, 35:1715-1737.
28. Adachi S., Uesugi T., Kamisaka K. Study of bilirubin metabolism by high-performance liquid chromatography: stability of bilirubin glucuronides. Arch. Biochem. Biophys. 1985, 241:486-493.
29. Doumas B.T., Perry B.W., Sasse E.A., Straumfjord J.V. Standardization in bilirubin assays: evaluation of selected methods and stability of bilirubin solutions. Clin. Chem. 1973, 19:984-993.
30. Seppen J., Bosma P.J., Goldhoorn B.G., Bakker C.T., Chowdhury J.R., Chowdhury N.R., Jansen P.L., Oude Elferink R.P. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J. Clin. Invest. 1994, 94:2385-2391.
31. Senafi S.B., Clarke D.J., Burchell B. Investigation of the substrate-specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 1994, 303(Pt 1):233-240.
32. Udomuksorn W., Elliot D.J., Lewis B.C., Mackenzie P.I., Yoovathaworn K., Miners J.O. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet. Genomics 2007, 17:1017-1029.
33. Zhou J., Tracy T.S., Remmel R.P. Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab. Dispos. 2010, 38:1907-1911.
34. Muraca M., Blanckaert N. Liquid-chromatographic assay and identification of mono- and diester conjugates of bilirubin in normal serum. Clin. Chem. 1983, 29:1767-1771.
35. Spivak W., Carey M.C. Reverse-phase h.p.l.c. separation, quantification and preparation of bilirubin and its conjugates from native bile. Quantitative analysis of the intact tetrapyrroles based on h.p.l.c. of their ethyl anthranilate azo derivatives. Biochem. J. 1985, 225:787-805.
36. Saxerholt H., Skar V., Midtvedt T. HPLC separation and quantification of bilirubin and its glucuronide conjugates in faeces and intestinal contents of germ-free rats. Scand. J. Clin. Lab. Invest. 1990, 50:487-495.
37. Mizobe M., Kondo F., Kumamoto K., Terada T., Nasu H. Rapid and quantitative analysis of bilirubin in equines by high-performance liquid chromatography. Microbios 1996, 86:39-47.
38. Zelenka J., Lenícek M., Muchová L., Jirsa M., Kudla M., Balaz P., Zadinová M., Ostrow J.D., Wong R.J., Vítek L. Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 867:37-42.
39. Cary P., Jodie J.V., Martin E.Q.J., Horacio P.A., David L. The animal pigment bilirubin identified in Strelitzia reginae, the bird of paradise flower. HortScience 2010, 45:1411-1415.
40. Messiano G.B., Santos R.A., Lde Ferreira S., Simões R.A., Jabor V.A., Kato M.J., Lopes N.P., Pupo M.T., de Oliveira A.R. In vitro metabolism study of the promising anticancer agent the lignan (-)-grandisin. J. Pharm. Biomed. Anal. 2013, 72:240-244.
41. Guidance for Industry: Bioanalytical Method Validation, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), United States Food and Drug Administration. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
42. Wu B., Zhang S., Hu M. Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Mol. Pharm. 2011, 8:2379-2389.
43. Christopoulos A., Lew M.J. Beyond eyeballing: fitting models to experimental data. Crit. Rev. Biochem. Mol. Biol. 2000, 35:359-391.
44. Takeda S., Kitajima Y., Ishii Y., Nishimura Y., Mackenzie P.I., Oguri K., Yamada H. Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab. Dispos. 2006, 34:1277-1282.
45. Lo S.F., Doumas B.T. The status of bilirubin measurements in U.S. laboratories: why is accuracy elusive. Semin. Perinatol. 2011, 35:141-147.
46. Diamond I., Schmid R. Experimental bilirubin encephalopathy. The mode of entry of bilirubin-14C into the central nervous system. J. Clin. Invest. 1966, 45:678-689.
47. Rodriguez Garay E.A., Scremin O.U. Transfer of bilirubin-14C between blood, cerebrospinal fluid, and brain tissue. Am. J. Physiol. 1971, 221:1264-1270.
48. Okamura Y., Yamazaki M., Yamaguchi T., Komoda Y., Sugimoto A., Nakajima H. Anti-bilirubin monoclonal antibody. III. Preparation and properties of monoclonal antibodies to unconjugated bilirubin-IX alpha. Biochim. Biophys. Acta 1991, 1073:538-542.
49. Kimpara T., Takeda A., Yamaguchi T., Arai H., Okita N., Takase S., Sasaki H., Itoyama Y. Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease. Neurobiol. Aging 2000, 21:551-554.
50. Otani K., Shimizu S., Chijiiwa K., Morisaki T., Yamaguchi T., Yamaguchi K., Kuroki S., Tanaka M. Administration of bacterial lipopolysaccharide to rats induces heme oxygenase-1 and formation of antioxidant bilirubin in the intestinal mucosa. Dig. Dis. Sci. 2000, 45:2313-2319.
51. Spivak W., Yuey W. Application of a rapid and efficient h.p.l.c. method to measure bilirubin and its conjugates from native bile and in model bile systems. Potential use as a tool for kinetic reactions and as an aid in diagnosis of hepatobiliary disease. Biochem. J. 1986, 234:101-109.